Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Centro De Ingeniera Genetica Y Biotecnologia

Centro De Ingeniería Geneética Y Biotechnología

Lisset Hermida Cruz

Gerardo Enrique Guillen Nieto

Aida Zulueta Morales

Laura Lazo Vazquez

Carlos Lopez Abarrategui

Rayner Rodriguez Diaz

Iris Valdes Prado

Maria Guadalupe Guzman Tirado

Beatriz De La Caridad Sierra Vazquez

Raul Rafael Espinosa Perez

Glay Chinea Santiago

Ricardo De La C Silva Rodriguez

Gerardo Enrique Guillén Nieto

Richardo De La C Silva Rodriguez

Laura Lazo Vázquez

Carlos López Abarrategui

Beatriz De La Caridad Sierra Vázquez

Susana Vázquez Ramundo

Iris Valdez Prado

Maria Guadalupe Guzmán Tirado

Alienys Izquierdo Oliva

Olga Lidia Pérez Guevara

Lázaro Gil González

Ernesto Marcos López

Edith Suzarte Portal

María Guadalupe Guzmán Tirado

Iris Valdés Prado

Angelica De La Caridad Garcia Arechavaleta

Mayling Alvarez Vera

Jorge Castro Velazco

Lázaro López Fernández

Rosa Liset Ramírez Bartutis

Yusleidi De La Caridad Pérez Fuentes

Yaremy Romero Fernández

Susana Vazquez Ramundo

Beatriz De Sierra Vazquez

Yusleidi De La Caridad PÉREZ Fuentes

Gerardo Enrique GUILLÉN Nieto

Angélica De La Caridad GARCÍA Arechavaleta

Guevara Olga Lidia PÉREZ

María Guadalupe Guzman Tirado

Aída Zulueta Morales

Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.

Dengue virus vaccine composition

The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein fromwith dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

Chimeric proteins that induce effects directed against viruses

This invention describes a pharmaceutical compound which has the capsid protein of Dengue virus and which is capable of inducing, in the receptor, a protective immune response before the viral challenge, without inducing the Ab-dependent enhancement phenomenon.

Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus

The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonspecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein fromwith dehydrogenase activity and fragments that codify for a region of the envelope (E) protein from the Dengue virus which, when inserted to an expression vector, give rise to chimeric proteins with particular properties. The resultant chimeric molecules from this invention are applicable to the pharmaceutical industry for the obtaining of vaccine preparations and diagnostic means of high serotype-specificity to be used in humans.

Growing community of inventors

Ciudad de la Habana, Cuba

Lisset Hermida Cruz